Menu

Maternal Response to Zika Damages Mouse Fetuses

Signaling pathways triggered by the mother’s immune system may cause complications during fetal development.

Jan 5, 2018
Catherine Offord

Mouse fetuses developing in Zika-infected mothers with normal immune signaling showed stunted growth and other abnormalities (right). By contrast, fetuses lacking key immune signaling proteins showed more normal development (left). SCI. IMMUNOL. 3, EAAO1680, 2018Some of the developmental damage observed in Zika-infected fetuses may be caused by the maternal immune system, according to a study published today (January 5) in Science Immunology. Researchers at Yale University found that mouse fetuses deprived of immune proteins known as interferon alpha/beta receptors (IFNARs) racked up fewer complications when their mothers were infected with the Zika virus than those with normally functioning proteins.

“We thought the fetuses missing this interferon receptor would be more susceptible to death from Zika infection,” study coauthor Akiko Iwasaki, a Yale immunologist, tells reporters, according to HealthDay News. “What we found was quite the opposite. . . . The fetuses unable to respond to interferon survived infection, and those that had the receptor, either they all died or were very small.”

IFNARs are activated by type I interferons (IFNs), antiviral proteins released by the mother’s immune system upon viral infection. Previous research in humans has suggested that the loss of IFNARs, and the subsequent pathway trigged by IFN signaling, is associated with greater susceptibility to Zika infection—indeed, the IFNAR-deficient fetuses in this study showed higher viral loads.

But the Yale team found that IFN signaling in mouse models also led to complications such as impaired development and death. What’s more, when the researchers activated the same pathway in cultured human placental tissue, they found deformities such as “knots”—abnormal structures associated with pregnancy-related pathologies. In short, “IFNAR-mediated pathology outweighed the benefit of IFNAR-dependent control of viral replication,” the authors write.

The team also discovered that the pathway triggered by IFNAR was dangerous to the fetus even in the absence of Zika infection, pointing to a possible role for the pathway in other types of problems during pregnancy. “The effects of IFN on the developing placenta likely have implications for pregnancy complications beyond ZIKV,” the team writes in the paper. “Our study implicates type I IFNs as a possible common culprit for virus-associated pregnancy complications and suggests blockade of type I IFNs as a possible intervention.” 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.